It has been known for many years that the Malassezia yeasts are associated with a n- ber of different human diseases ranging from pityriasis versicolor to seborrhoeic d- matitis. However the evolving history of their taxonomy and pathogenicity, and the management of the diseases that they cause has been a long, and often diffcult, jou- ney. Their fastidious growth requirements defed the initial attempts to culture these organisms on laboratory media and their true identifcation and the relationship between different species only became apparent with the application of modern molecular techniques. Likewise although recognised in the 19th century as potential causes of human infection, piecing together the complex and, in certain cases, still uncertain relationships to different human diseases has taken many years. Recognised initially as causes of infection of the skin, they are now known to be superfcial c- mensals as well as potential causes of infections in domestic animals and more serious human conditions such as fungemia. They have also been implicated in the pathog- esis of allergic and other infammatory diseases. Given this complex, yet fascinating, history it seems appropriate to bring together current thought on these yeasts, their structure and function and their association with both human and animal disease states. This book provides such a view of the genus Malassezia and the diseases caused by its members.

Here, renowned researchers in bioanalysis present in-depth reviews of recent trends in the field. Coverage includes topics such as aptamers, bioelectroanalysis, nanoparticles, quantitative NMR, mass spectrometry, immunosensors and -assays, or chiral electromigration techniques. Originally published in the journal Bioanalytical Reviews, these outstanding contributions are now available in a hardcover print format. This volume benefits in particular those research groups and libraries that have chosen to have only electronic access to the journal. It also provides valuable content for all researchers in bioanalytical science.

Known for flexibility and robustness, PCR techniques continue to improve through numerous developments, including the identification of thermostable DNA polymerases which exhibit a range of properties to suit given applications. PCR Protocols, Third Edition selects recently developed tools and tricks, contributed by field-leading authors, for the significant value that they add to more generally established methods. Along with the cutting-edge methodologies, this volume describes many core applications, such as PCR cloning and sequencing, expression, copy number or methylation profile analysis, 'DNA fingerprinting', diagnostics, protein engineering, interaction screening as well as a chapter highlighting workflow considerations and contamination control, crucial for all PCR methods. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary reagents and materials, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and up-to-date, PCR Protocols, Third Edition seeks to further elucidate this essential technique while also providing core principles with broad applications for scientists of all backgrounds.

Initially genetic disorders were all considered as rare diseases. At present, in the mid of 2009, the OMIM catalogue contains information on more than 12 000 entries of which about 2500 are available for clinical testing based on the identification of the responsible gene defect. However, altogether it has been estimated that about 8 percent of a population in the economically developed countries will during their lifetime suffer from a disease mainly as the result of their genetic constitution. Adding to that, it is estimated that all diseases have a genetic component, which will determine who will be at a higher than average risk for a certain disorder. Further it is postulated that in the near future, this genetic profiling could become useful in selecting an appropriate therapy adapted to the genetic constitution of the person. Thus, genetic disorders are not rare. Measuring quality of health care related processes became an issue in the 1990s, mainly in laboratory medicine, but also for hospitals and other health care systems. In many countries national authorities started to implement recommendations, guidelines or legal procedures regulating quality of health care delivery. In laboratory medicine, in parallel, the use of accreditation as a method assuring high quality standards in testing came in use. With the increasing possibilities of performing molecular genetic testing, genetic laboratories needed to become involved in this process. As many genetic disorders are rare, most laboratories worldwide offered analysis for a specific set of disorders, and, therefore, very early on a transborder flow of samples occurred. While international quality criteria (ISO) have been in existence for a number of years, the regulation of quality issues still may differ between countries. Based on their personal experience in the varying fields of quality research and clinical implementation of quality criteria in genetic services the authors of this book share their experience and give examples of the implementation of quality issues in national quality systems worldwide. This book, which is the result of the effort of many persons, is destined to aid laboratory managers and counsellors, health care managers and other stakeholders in national or international health care service to improve the services to the benefit of patients with suspected genetic disorders.

In this book, Dr. Li and his author team plan to emphasize why mouse models are useful in vivo systems for understanding disease mechanisms and developing therapeutic strategies in blood cancers. The authors do not intend to cover all types of blood cancers; instead, they will focus on some major ones such as leukemias and lymphomas. However, the authors will try to cover as much as they can the cancer types and point out that many blood cancers need to be studied in mouse disease models although they are still not available at present. A major focus in the book will be to show what we can or cannot learn from mouse disease models and to also show the critical contributions of mouse models in therapeutic drug development.

A lot of research on biomarkers for Alzheimer is being done in the last few decades. The aim of these studies is to find some method to ease the diagnosis of Alzheimers as early as possible. Such methods are a range of blood or CSF tests on one hand and several types of neuroimaging scans on the other. Many of the images coming both from laboratory and neuroimaging are very visual and illustrative. These images, accompanied by a short description, can perfectly explain the main results and usefulness of every biomarker. The objective of this book would be to summarize the most important studies made in this field. Few publications have systematically compiled results on this topic and only one as an atlas. Readers would be interested in this publication because it allows reviewing the current status of research by handily visualizing the results.

"Development of novel vaccines" gives an overview of the tasks in basic research leading to the final product - the vaccine and its applications, belonging to the most complex biologics in the pharmaceutical field. Distinct from most textbooks in the vaccine arena, the current issue focuses on the translational aspect, namely, how research results can be transformed into life-saving medical interventions. Each chapter of the book deals with one important paradigm for the development of novel vaccines, along the value chain towards the final vaccine, and furthermore, with the inevitable tools required for this process. Contributions are prepared by teams of scientists, all of whom are experts in the field, most of them anchored in biomedical organizations devoted to translational culture, thereby lighting the certain topics from different views. This volume is a must read for researchers engaged in vaccine development and who really want to see their research results to become a product.

This book is the2nd improved and expanded edition of "Clinical Enzymology" (Lott/Wolf, 1987). It includes case studies and guidelines for specialists of laboratory medicine and clinicians, devotes each chapter to a specific enzyme or protein marker, contains case studies and guidelines, a section on marker biochemistry and physiology as well as a section on special pathology and analysis. The clear, didactic structure and the multiple choice questions also make the book valuable reading for graduate students in the fields of clinical pathology and laboratory medicine.

Therapeutic regimens for visceral leishmaniasis (also Kala-azar, Dum-dum fever or black fever), caused by parasitic protozoa of the Leishmania genus, evolve at a pace never seen before. Spread by tiny and abundant sand flies, the parasite infects internal organs and bone marrow and if left untreated will almost always result in the death of the host. In developing countries successful diagnosis and treatment are complicated by asymptomatic cases, undernutrition and Kala-azar/HIV co-infections. This book brings together world-renown experts writing state-of-arts review on the progress in diagnosis and treatment of visceral leishmaniasis, ultimately leading to the complete elimination of this fatal disease from South Asia. The chapters provide valuable information for disease control as well as therapy and the diagnostic improvements necessary for early treatment, subclinical detection and drug-resistant cases. The presented methods allow for points-of-care testing in the endemic area, enabling rapid detection in resource-poor settings with easy handling and low costs. This book provides essential information for scientists, medical practitioners and policy makers involved in the diagnosis, treatment and elimination of Kala-azar.

The unexpected and premature passing away of Professor Ebrahim H. "Abe" Mamdani on January, 22, 2010, was a big shock to the scientific community, to all his friends and colleagues around the world, and to his close relatives. Professor Mamdani was a remarkable figure in the academic world, as he contributed to so many areas of science and technology. Of great relevance are his latest thoughts and ideas on the study of language and its handling by computers. The fuzzy logic community is particularly indebted to Abe Mamdani (1941-2010) who, in 1975, in his famous paper An Experiment in Linguistic Synthesis with a Fuzzy Logic Controller, jointly written with his student Sedrak Assilian, introduced the novel idea of fuzzy control. This was an elegant engineering approach to the modeling and control of complex processes for which mathematical models were unknown or too difficult to build, yet they could effectively and efficiently be controlled by human operators. This ground-breaking idea has found innumerable applications and can be considered as one of the main factors for the proliferation and adoption of fuzzy logic technology. Professor Mamdani's own life and vital experience are illustrative of his "never surrendering" attitude while facing adversaries, which is normal for a person proposing any novel solution, and represent a great example for everybody. His subtle sense of humor, his joy for life, and his will to critically help people, especially young people, were characteristics deeply appreciated by all the people who enjoyed and benefited from his friendship and advice. This book constitutes a posthumous homage to Abe Mamdani. It is a collection of original papers related in some way to his works, ideas and vision, and especially written by researchers directly acquainted with him or with his work. The underlying goal of this book will be fulfilled if, in the very spirit of Mamdani's legacy, the papers will trigger a scientific or philosophical debate on the issues covered, or contribute to a cross-fertilization of ideas in the various fields.

The objective of this volume is togive an overview of the present state of the art of pediatric clinical pharmacology including developmental physiology, pediatric-specific pathology, special tools and methods for development of drugs for children (assessment of efficacy, toxicity, long-term safety etc.) as well as regulatory and ethical knowledge and skills. In the future, structural and educational changes have to lead back to a closer cooperation and interaction of pediatrics with (clinical) pharmacology and pharmacy."

The book highlights work from many different labs that taught us abnormal HDACs potentially contribute to the development or progression of many human diseases including immune dysfunctions, heart disease, cancer, memory impairment, aging, and metabolic disorders.

In this accessible overview of current knowledge, an expert team of editors and authors describe experimental approaches to consciousness. These approaches are shedding light on some of the hitherto unknown aspects of the distinct states of human consciousness, including the waking state, different states of sleep and dreaming, meditation and more. The book presents the latest research studies by the contributing authors, whose specialities span neuroscience, neurology, biomedical engineering, clinical psychology and psychophysiology, psychosocial medicine and anthropology. Overall this anthology provides the reader with a clear picture of how different states of consciousness can be defined, experimentally measured and analysed. A future byproduct of this knowledge may be anticipated in the development of systematic corrective treatments for many disorders and pathological problems of consciousness.

A comprehensive reference work: This looseleaf work is an authoritative compilation of methods for the detection of autoantibodies (Section A: Methods of Autoantibody Detection); the structure, function, and molecular and biochemical concepts of autoantigens (Section B: Autoantigens); and the clinical significance of measuring autoantibodies in patients with rheumatic, connective tissue and autoimmune diseases (Section C: Clinical Significance of Autoantibodies). This unique work brings together all the molecular and medical information - very difficult to retrieve otherwise - in ONE publication. The Editors and contributors are leading experts in the immunological, molecular biological, and clinical fields. The format of this looseleaf publication allows regular updating of data as well as inclusion of new advances in research on autoimmunity. Until now, the work (Basic work including Supplement 1) included Section A, and the larger part of Section B, both in an attractive and robust ringbinder. Audience: By nature and design of this exciting reference work, it is especially aimed at scientists, including immunologists, pathologists and molecular biologists, and clinical chemists, as well as clinicians specializing in rheumatic diseases and autoimmune disorders, inflammation or clinical immunology. Supplement 2: This supplement primarily contains Section C (Clinical Significance of Autoantibodies). As in the other sections, the contents are presented in a consistently structured manner, beautifully illustrated with photos and schematic figures. Extensive literature references are provided. Also, this supplement includes an addition to Section B (Autoantigens), being chapter B.1.5: The Antigens Defined by Antikeratin Antibodies (AKA).

This proposed text appears to be a good introduction to evolutionary computation for use in applied statistics research. The authors draw from a vast base of knowledge about the current literature in both the design of evolutionary algorithms and statistical techniques. Modern statistical research is on the threshold of solving increasingly complex problems in high dimensions, and the generalization of its methodology to parameters whose estimators do not follow mathematically simple distributions is underway. Many of these challenges involve optimizing functions for which analytic solutions are infeasible. Evolutionary algorithms represent a powerful and easily understood means of approximating the optimum value in a variety of settings. The proposed text seeks to guide readers through the crucial issues of optimization problems in statistical settings and the implementation of tailored methods (including both stand-alone evolutionary algorithms and hybrid crosses of these procedures with standard statistical algorithms like Metropolis-Hastings) in a variety of applications. This book would serve as an excellent reference work for statistical researchers at an advanced graduate level or beyond, particularly those with a strong background in computer science.

Healthcare and Biotechnology in the 21st Century: Concepts and Case Studies introduces students not pursuing degrees in science or engineering to the remarkable new applications of technology now available to physicians and their patients and discusses how these technologies are evolving to permit new treatments and procedures. The book also elucidates the societal and ethical impacts of advances in medical technology, such as extending life and end of life decisions, the role of genetic testing, confidentiality, costs of health care delivery, scrutiny of scientific claims, and provides background on the engineering approach in healthcare and the scientific method as a guiding principle. This concise, highly relevant text enables faculty to offer a substantive course for students from non-scientific backgrounds that will empower them to make more informed decisions about their healthcare by significantly enhancing their understanding of these technological advancements.

Blood transfusion is considered a life-saving therapy since ancient times, but, at the same time, a high-risk procedure. Nowadays the common perception is that infection is the greatest risk, even if the blood has never been safer from this point of view. Currently, the residual risk of transfusion must be related mainly to immunological mechanisms underlying to AB0 and minor blood systems, to compatibility of blood transfused and to development of irregular antibodies in transfused patients. "Transfusion Medicine and Patient Safety" aims to provide the basic of immunohematology to readers and to analyze the transfusional process highlighting the most critical points, thus more exposed to errors. Screening on blood and blood components for infectious diseases along with the surveillance action on emerging viruses results in the drastic reduction of post-transfusion infection, together with the potential to further increase the level of security from infection through the inactivation of blood components. The text also describes the major diagnostic systems and organizational models that modern technology provides us with a correct immunohematological diagnosis and an appropriate trasfusional therapy.

The goal of clinical laboratories is to produce accurate information for clinical decision making in medicine. More than half of the medical decisions made depend on clinical laboratory tests. Patient safety represents an important and critical problem for laboratories. They need to assure that the information they deliver to physicians is accurate, and therefore safe for clinicians to use. Endogenous compounds can interfere with laboratory tests, decreasing accuracy and threatening patient safety. Elevated bilirubin (bilirubinemia) and elevated lipids (lipemia) are common conditions that cause significant interferences with laboratory results. Clinicians depend on laboratories to detect these endogenous interferences. Laboratories must have a means to detect these endogenous interferences, make decisions about reporting results, and evaluate their impact. Most clinical pathology books provide only an abbreviated introduction to the subject, or provide a long list of references, without the necessary foundation for evaluating their significance. Package inserts typically provide scant information. This book provides the empirical and theoretical foundation for these interferences, describes the clinical settings where they occur, and explains their evaluation and detection, allowing the laboratory to interpret the available data on interferences and make the appropriate decision to effectively report test results while protecting patient safety.

Immunofluorescence, a suitable laboratory method for the microscopic demonstration of antigens and antibodies in biological materials, useable, for example, to provide evidence for the pathogenesis of disease in histological or cytological preparations and for tumour cell differentiation. For this reason immunofluorescence has a decisive role as the method of choice for the diagnosis of auto-immune diseases. This primer on immunofluorescence techniques, which first appeared in 1979, is a richly illustrated handbook suitable for everyday practical work in the laboratory, useable as both an introduction to the subject as well as an atlas. In hardly any other area of medicine are there so many new findings to report. The second edition of this book is concerned not only with the detection methods which now form an essential and established part of diagnostic techniques, but also with the most recent research results such as the discovery of antibodies against Auerbach's plexus and against podocytes...

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.

Molecular biology has rapidly advanced since the discovery of the basic flow of information in life, from DNA to RNA to proteins. While there are several important and interesting exceptions to this general flow of information, the importance of these biological macromolecules in dictating the phenotypic nature of living creatures in health and disease is paramount. In the last one and a half decades, and particularly after the completion of the Human Genome Project, there has been an explosion of technologies that allow the broad characterization of these macromolecules in physiology, and the perturbations to these macromolecules that occur in diseases such as cancer. In this volume, we will explore the modern approaches used to characterize these macromolecules in an unbiased, systematic way. Such technologies are rapidly advancing our knowledge of the coordinated and complicated changes that occur during carcinogenesis, and are providing vital information that, when correctly interpreted by biostatistical/bioinformatics analyses, can be exploited for the prevention, diagnosis, and treatment of human cancers. The purpose of this volume is to provide an overview of modern molecular biological approaches to unbiased discovery in cancer research. Advances in molecular biology allowing unbiased analysis of changes in cancer initiation and progression will be overviewed. These include the strategies employed in modern genomics, gene expression analysis, and proteomics.

This book offers a description of current and recently developed laboratory assays in the field of haemostasis and thrombosis. It is the result of a unique cooperation between experts from more than 60 institutes in 12 European countries, brought together by the ECA T (European Concerted Action on Thrombosis and Disabilities) under the auspices of the Commission of the European Communities in Brussels, Belgium. The ECAT, which was initiated in 1981, designed and performed three prospective clinical studies to establish haemostatic factors as risk indicators of thrombosis. Included were patients with angina pectoris at risk from myocardial infarction, patients undergoing angioplasty at risk from re-stenosis, and patients receiving hip replacement at risk from deep venous thrombosis. Assay procedures were chosen, training courses for technicians held, and essential reagents were supplied from a central source. A quality control assessment scheme served to compare assay results both within and between laboratories. In the angina pectoris study, centres determined most of the assays locally; in the other two studies assays were performed centrally. The need for further quality assessment in Europe Dr J. F. Davidson in Glasgow, led to a separate activity coordinated by including coagulation inhibitors and plasminogen as risk factors for familial venous thrombosis. The Editors hope the ECA T Assay Procedures book will contribute to further harmonization ofhaemostasis assays, and ultimately to their standardization.

Transfusion medicine provides an excellent bridge connecting the healthy community donors with the patient's needs at the bedside; the dominant philosophy has been on patient care and science, but it is now realised that blood banks manufacture increasing amounts of blood components to administer to patients -- a role analogous to manufacturing functions. The concept of Good Manufacturing Practice (GMP) is therefore relatively new. While quality has always been important, the impact of GMP, Total Quality Management (TQM) and Quality Assurance (QA) will be profound. As the regulatory agencies, like the FDA in the U.S.A. and the EEC Commission in Europe, increase their enforcement activities, doctors, technical experts and managers will have to face many issues of quality assurance including documentation, validation, audit system, regulatory laws, licensing, teaching and training of staff and their job descriptions, standards, processing facilities, procedure validations, automation, record keeping, internal and external quality control of products and their release.The expansion of this philosophy to include Good Clinical Practice (GCP) is an even greater challenge demanding consensus therapy protocols and quality management of transfusion through auditing by the hospital transfusion committees. Such comprehensive plans will profoundly affect the financial and organisational structure of blood transfusion in the future.

In transfusion medicine the scientific fundamentals of immunology have had a considerable clinical impact. Transfusion may suppress the immunity but some patients could suffer disadvantages including GvHD, alloimmunisation and possible cancer, where white cells (WBC) play pivotal roles in this phenomenon, presenting antigens and producing cytokines. A clinical application of this practice is LAK-cells targeted against cancer. MHC on the WBC may provide additional immunological modulations through series of secondary messengers. Thus reduction of WBC in the blood and bone marrow may be advantageous for patients. On the other hand, sharing a part of MHC or making the transplanted white cells anergic by storage may be even more advantageous for patients. CMV infection could mimic part of this MHC. UV radiation is effective in the inactivation of the WBC although filters are easy means for such removal. However, their accurate quantification requires flow cytometry that has considerable potential application in blood transfusions. Idiotypic antibody could play an important role in platelet theory. However, the potential infection risks in transfusion like HIV and HCV remain, but application of molecular biological methods like PCR or RT/PCR has great potentials in detection of infectious diseases, transplantation and genetic disorders. Immuno affinity purified concentrates, like factor IX and protein C, could reduce patients' immune functions, where in the future protein C could be derived from transgenic animals. Advances are sure to emerge through adoptive immunotherapy and gene therapies are exciting prospects when genes transferred into lymphocytes could be used to correct cell mediated immune deficiency, as in ADA.

380 years ago, in the year 1614, Ubbo Emmius transplanted the gene ofscience from Ostfriesland into the education genome ofthe city ofGroningen as devel- oped by Regnerus Praedinius. He thereby founded the University ofGroningen. It is with great pleasure that the Faculty of Medicine as one of the founding faculties ofour University, welcomes you to this 19th International Symposium ofBloodTransfusion, whichwill coverthe themeofHereditaryDiseasesandtheir relation to Transfusion Medicine, where cell expansion, gene transfer and gene therapy are the read thread. Since the earlydays there has beena specificand sincere interest in inborn errors ofmetabolism and hereditarydisorders. This interest has resulted in a structured research, diagnostic and counselling facilities, and therapeuticapproaches where various disciplines within our faculty work closely together with groups from related faculties of the University of Groningen, as well as other national and international scientific institutions. The field of inborn errors, genetic abnormalities and mutations, and hereditary diseases covers a broad gamma of extremely interesting and exciting scientific aspects,whichrangefrom clearphysicalaberrationstomolecularanalysisofgenes and genomes, coding areas and amino acid sequences. It is intriguing to realise that the balance of life seemingly depends on the position or presence of one single molecule as a part ofthe total complex ofgenetic information in the cell.